Investment Thesis
Greenwich LifeSciences is a pre-revenue pharmaceutical company with severe financial distress. With $3.8M in total assets, -$6.7M annual operating cash burn, and no revenue generation, the company has less than 7 months of cash runway at current burn rates. Deteriorating EPS (-75.4% YoY) and massive negative returns (ROE -523.4%, ROA -300.4%) indicate the company is in early development with high execution risk and limited margin for error.
Strengths
- Zero long-term debt provides financial flexibility
- Strong liquidity position (17.82x current ratio) delays immediate solvency risk
- Typical pre-revenue biotech structure appropriate for development-stage company
Risks
- No revenue reported - fundamental absence of commercial traction in pharmaceutical sector
- Negative operating cash flow of -$6.7M with only $3.8M in cash reserves (~7 months runway)
- Deteriorating EPS declining 75.4% YoY indicates accelerating losses
- Minimal balance sheet ($3.8M assets) provides almost no buffer for setbacks
- Very limited insider activity (2 Form 4 filings in 90 days) suggests low engagement or confidence
Key Metrics to Watch
- Cash burn rate and remaining runway - critical for survival assessment
- Revenue recognition milestone - path to commercial viability
- Operating loss trends and timeline to profitability
- Clinical trial progress and regulatory approval status
Financial Metrics
Revenue
N/A
Net Income
-11.4M
EPS (Diluted)
$-0.85
Free Cash Flow
-6.7M
Total Assets
3.8M
Cash
3.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-523.4%
ROA
-300.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
17.82x
Quick Ratio
17.82x
Debt/Equity
0.00x
Debt/Assets
42.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-10T13:36:20.598712 |
Data as of: 2025-09-30 |
Powered by Claude AI